Competition Among Pathogenic or Protective T Cell Clones
Competition Among Pathogenic or Protective T Cell Clones
批准号:
7071656
负责人:
ELI E SERCARZ
金额:
$39.99万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 2009-06-30
关键词:
AdenoviridaeLeishmania majorMHC class II antigenT cell receptorantigen presentationautoimmunitybacterial antigenscell adhesioncell cell interactioncell differentiationcell migrationcommunicable diseasesconfocal scanning microscopycytokineenzyme linked immunosorbent assayexperimental allergic encephalomyelitisgenetic polymorphismgenetically modified animalshelper T lymphocyteimmune responselaboratory mouseleishmaniasisligandsprotein biosynthesistissue /cell culturetransfection /expression vector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In this proposal, we will try to achieve knowledge of the types of competitive interactions that occur in autoimmune and in infectious situations, both with unprimed naive populations and with primed memory cells. There are many elements involved in establishing repertoire choice, at the MHC and at the T cell levels. From an enormous repertoire of potential players, very often a small group of clones with characteristics that enhance disease emerge as "drivers" of the disease process. Often, such driver clones repeatedly occur in most individuals of the genetically restricted population. We would like to understand how such cells gain a competitive advantage. In the autoimmune encephalomyelitis (EAE) model of the B10.PL H-2u mouse, there are three transgenic lines of mouse all specific for the dominant determinant Acl-9 at the amino terminus of myelin basic protein. These transgenic cells will be followed for their early appearance, migratory properties, changing pattern of memory and adhesion surface markers, and cytokine/chemokine production and receptor patterns throughout the disease course. Are the drivers of autoimmunity always Th1 cells, always public, and of high affinity? The three clones will then be placed in competitive situations and we will ask under which conditions an advantage is gained by one of them. Does this advantage occur at the very outset of binding to the antigen presenting cell? Or during the early days of neonatal (lymphopenic) life? What evidence is there for in vivo clonal competition? In these studies, CDR3-1ength polymorphism will be used to follow the unique structures of these clonal receptors, and ELISAspot analysis as well as CFSE tracing of division, and confocal imaging of specific cluster formation will serve to study the competitive interactions. In the infectious disease world, the driver of disease, again found in many individuals, is more often than not, a Th2 cell, preventing the development of a successful defense. In the leishmanial system which we are studying, we plan to skew the response with adenovirus vectors containing cytokine genes, so that previously susceptible animals such as the BALB/c, treated with IL-12-bearing-adenovirus, now becomes resistant, and now we will explore the probability of defining a protective (set of) clone(s) in this mouse. Such protective clones could be compared to those found in the initially resistant B10.D2. Likewise, we will study the dominant determinant in the Leishmania homologue of mammalian RACK (=LACK) and its variants to examine the nature of pathogenic Th2 driver clones. In each of the opposite disease models of autoimmunity and infectious disease, it is of great interest that the defense of the body might be under the control of a particularly predominant clonal population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
B cell regulation of diabetogenic activity
-
批准号:7196856
-
项目类别:
-
资助金额:$45.5万
-
财政年份:2007
-
负责人:ELI E SERCARZ
-
依托单位:
B cell regulation of diabetogenic activity
-
批准号:7385968
-
项目类别:
-
资助金额:$44.64万
-
财政年份:2007
-
负责人:ELI E SERCARZ
-
依托单位:
Degeneracy and Complexity in the Immune System
-
批准号:7059192
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2006
-
负责人:ELI E SERCARZ
-
依托单位:
PATHOGENIC AND REGULATORY AUTOIMMUNE T CELL REPERTOIRES
-
批准号:6606941
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2000
-
负责人:ELI E SERCARZ
-
依托单位:
PATHOGENIC AND REGULATORY AUTOIMMUNE T CELL REPERTOIRES
-
批准号:6374611
-
项目类别:
-
资助金额:$32.9万
-
财政年份:2000
-
负责人:ELI E SERCARZ
-
依托单位:
PATHOGENIC AND REGULATORY AUTOIMMUNE T CELL REPERTOIRES
-
批准号:6511557
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2000
-
负责人:ELI E SERCARZ
-
依托单位:
PATHOGENIC AND REGULATORY AUTOIMMUNE T CELL REPERTOIRES
-
批准号:6191305
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2000
-
负责人:ELI E SERCARZ
-
依托单位:
Competition Among Pathogenic or Protective T Cell Clones
-
批准号:6828690
-
项目类别:
-
资助金额:$30.71万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL MATURATION AND LIGAND QUALITY
-
批准号:6137246
-
项目类别:
-
资助金额:$29.05万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
Competition Among Pathogenic or Protective T Cell Clones
-
批准号:6726358
-
项目类别:
-
资助金额:$10.24万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
Competition Among Pathogenic or Protective T Cell Clones
-
批准号:6891332
-
项目类别:
-
资助金额:$40.95万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL MATURATION AND LIGAND QUALITY
-
批准号:6626339
-
项目类别:
-
资助金额:$31.74万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
Competition Among Pathogenic or Protective T Cell Clones
-
批准号:7240572
-
项目类别:
-
资助金额:$38.83万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL MATURATION AND LIGAND QUALITY
-
批准号:6488700
-
项目类别:
-
资助金额:$29.26万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
Competition Among Pathogenic or Protective T Cell Clones
-
批准号:7455255
-
项目类别:
-
资助金额:$38.09万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL MATURATION AND LIGAND QUALITY
-
批准号:2758880
-
项目类别:
-
资助金额:$28.2万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL MATURATION AND LIGAND QUALITY
-
批准号:6684862
-
项目类别:
-
资助金额:$3.1万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL MATURATION AND LIGAND QUALITY
-
批准号:6341694
-
项目类别:
-
资助金额:$29.92万
-
财政年份:1999
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL RESPONSE TO MEP-REPERTOIRE AND REGULATION
-
批准号:2064447
-
项目类别:
-
资助金额:$17.05万
-
财政年份:1989
-
负责人:ELI E SERCARZ
-
依托单位:
T CELL RESPONSE TO MEP-REPERTOIRE AND REGULATION
-
批准号:2886617
-
项目类别:
-
资助金额:$23.88万
-
财政年份:1989
-
负责人:ELI E SERCARZ
-
依托单位:
海外基金